GET DAILY SIGNALSJasper Therapeutics (JSPR) Q3 2026 Earnings Outlook: Pipeline Progress and Cash Runway in Focus
Key Takeaways
- Jasper Therapeutics (JSPR) is expected to report results for the third quarter of 2026 (the three months ended September 30, 2026) in early-to-mid November 2026.
- Consensus estimates point to a net loss of roughly $0.06 per share, a significant improvement from the $1.13 loss reported in the same quarter a year earlier.
- Some analysts model between $6 million and $12 million in quarterly revenue, which would mark a notable step up from the $0 recorded in the prior-year period.
- Investors will focus on briquilimab clinical progress, research and development (R&D) spending, and the company's cash runway.
- Jasper's most recent report (Q2 2026) showed a loss of $0.10 per share, beating consensus of about $0.27, yet shares have remained under pressure.
- For more detail on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated Tickeron pages.
- Explore Trending AI Robots for automated trading strategies and real-time market insights.
Why This Earnings Report Matters
Jasper Therapeutics is a clinical-stage biotechnology company whose lead candidate, briquilimab, targets the CD117 (c-Kit) receptor to address mast cell-driven diseases such as chronic spontaneous urticaria (CSU, a form of chronic hives) and chronic inducible urticaria (CIndU). Because the company does not yet generate product revenue, its quarterly updates are less about sales and more about pipeline execution, clinical data timing, and cash management. This report matters because it will show how quickly Jasper is spending on its trials and how far its balance sheet can carry its programs toward the next catalysts. For investors, the release serves as a checkpoint on both near-term milestone timing and the company's potential need for additional capital. I also checked this using Tickeron’s AI Screener to see how JSPR compares to others in the industry.
What Analysts Expect for Q3
For the third quarter of 2026, Wall Street's consensus centers on a net loss of roughly $0.06 per share, with individual estimates ranging near $0.06 to $0.08. That compares with a loss of $1.13 per share in the year-ago quarter, reflecting a substantially narrower expected loss. On the revenue line, a subset of analysts models between roughly $6 million and $12 million, whereas Jasper historically reports no product revenue, so any collaboration or licensing recognition would be a meaningful signal to watch.
For context, Jasper's last report (the second quarter of 2026, released in August) delivered a loss of $0.10 per share, beating consensus of about $0.27. The company has beaten EPS (earnings per share) expectations in several recent quarters, though its shares have still trended lower. Key metrics investors will scrutinize include R&D expense, cash and equivalents on hand, and any commentary on the durability of the company's runway.
Recent Performance and Market Reaction
Sentiment heading into the Q3 2026 report remains cautious. Jasper's shares have traded near $0.50 in recent weeks, well below their levels of a year earlier, as development-stage risk and dilution concerns weigh on the stock. The company's prior earnings release in August 2026 was followed by continued selling pressure, and data trackers note a negative post-earnings drift since that report. Investors are not merely trading the bottom-line loss; they are positioning around clinical catalysts, financing needs, and whether the company can demonstrate progress on briquilimab's path toward late-stage development. Key risks heading into the print include any indication of higher-than-expected cash burn, a delayed catalyst timeline, or the absence of revenue recognition that some analysts have begun to model.
What to Watch Going Forward
Looking beyond the upcoming print, investors should track several forward-looking themes. First is briquilimab's clinical progress in chronic urticaria and lower-risk myelodysplastic syndromes (MDS, a group of blood disorders), where data readouts and regulatory interactions will shape the company's trajectory. Any updated timing for pivotal studies or discussions with regulators would be a significant catalyst.
Second is the balance sheet. As a pre-revenue company, Jasper's cash runway and R&D spending trends will be closely watched. If the report signals an accelerated burn rate, attention may shift to the timing and terms of potential future financings, which can affect existing shareholders.
Third is revenue recognition. If analysts' early revenue estimates reflect a new collaboration or partnership, confirmation of those economics could change how the market values the company. Finally, investors should watch broader sentiment toward small-cap and clinical-stage biotechnology stocks, which can amplify price moves around earnings regardless of the company's fundamentals.
AI Tools in Biotech Research
From what I see, tools like Tickeron’s AI Screener have become a regular part of my workflow when evaluating clinical-stage names. It lets me quickly filter for patterns in volatility, sector momentum, and fundamental trends across thousands of stocks. For a name like JSPR, this kind of scan helps put the upcoming earnings release in broader context without having to comb through data manually.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
JSPR saw its Stochastic Oscillator peaks and leaves the overbought zone
The Stochastic Oscillator for JSPR moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 44 similar instances where the indicator exited the overbought zone. In 41 of the 44 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JSPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
JSPR broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JSPR entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on JSPR as a result. In 75 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for JSPR just turned positive on October 23, 2026. Looking at past instances where JSPR's MACD turned positive, the stock continued to rise in 32 of 37 cases over the following month. The odds of a continued upward trend are 86%.
Following a +6.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where JSPR advanced for three days, in 203 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. JSPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: JSPR's P/B Ratio (397.034) is very high in comparison to the industry average of (3.498). P/E Ratio (-18.129) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JSPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement